Nivolumab: beside an established treatment under test
112 studies: an approved drug, surgery or radiation is what the study tests. Page 2 of 2. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.
- Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)TerminatedNCT03354962Phase 1/2Report a problem
- Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT03238365Early Phase 1Report a problem
- Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibActive, not recruitingNCT03235245Phase 2Report a problem
- UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.CompletedNCT03224871Early Phase 1Report a problem
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal CarcinomatosisActive, not recruitingNCT03172416Phase 1Report a problem
- Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03161756Phase 1/2Report a problem
- Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLCCompletedNCT03044626Phase 2Report a problem
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2Report a problem
- A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaCompletedNCT02857569Phase 1/2Report a problem
- Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal CancerCompletedNCT02848443Phase 1Report a problem
- Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedNCT02719613Phase 2Report a problem
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3Report a problem